Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277350 | 0.91 | ALDH1A1 (0.53) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6278248 | 0.88 | ALDH1A1 (0.56) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6282326 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6287389 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6283853 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6278020 | 0.79 | KCNH2 (0.59) | LMNAKMT2AMAPTMEN1 | |
| SCHEMBL6283840 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6278291 | 0.75 | LMNA (0.47) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL6283657 | 0.75 | ALDH1A1 (0.54) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| SCHEMBL10086152 | 0.73 | HPGD (0.56) | ALDH1A1HSD17B10KDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | ALDH1A1 1363/4885HSD17B10 3120/4885KDM4E 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.